cytosolic delivery of endocytosed materials. Outstandingly, the cytotoxicity of MTX-loaded CS-NPs was higher than free drug to MCF-7 tumor cells and, to a lesser extent, to HeLa cells. Based on the overall results, MTX-CS-NPs modified with the pH-sensitive surfactant 77KS could be potentially useful as a carrier system for intracellular drug delivery and, thus, a promising targeting anticancer chemotherapeutic agent.
Introduction
Cancer is one of the main causes of mortality worldwide and the World Health Organization (WHO) estimates that there will be 15 million new cases of cancer worldwide in 2020 (ETPN 2015) . The clinical efficacy of conventional treatments is often compromised by the acquisition of resistance in cancer cells and/or by the generation of several side effects to the patients (Banerjee et al. 2002; Dong and Mumper 2010) . In this context, nanotechnology-based pharmaceutical products might provide a wide range of new tools and possibilities in cancer therapy, from earlier diagnostics to more efficient and more targeted treatments (Chen et al. 2014; Das and Sahoo 2011; Li et al. 2012) .
Methotrexate (MTX) is a cytotoxic drug used in the therapy of solid tumors and leukemias. Its main pharmacological target is the competitive inhibition of dihydrofolatereductase (DHFR), an intracellular enzyme that reduces folic acids to key intermediates in several important biochemical pathways of DNA and RNA synthesis (Gonen and Assaraf 2012) . Unfortunately, the resistance in cancer Abstract The encapsulation of antitumor drugs in nanosized systems with pH-sensitive behavior is a promising approach that may enhance the success of chemotherapy in many cancers. The nanocarrier dependence on pH might trigger an efficient delivery of the encapsulated drug both in the acidic extracellular environment of tumors and, especially, in the intracellular compartments through disruption of endosomal membrane. In this context, here we reported the preparation of chitosan-based nanoparticles encapsulating methotrexate as a model drug (MTX-CS-NPs), which comprises the incorporation of an amino acid-based amphiphile with pH-responsive properties (77KS) on the ionotropic complexation process. The presence of 77KS clearly gives a pH-sensitive behavior to NPs, which allowed accelerated release of MTX with decreasing pH as well as pH-dependent membrane-lytic activity. This latter performance demonstrates the potential of these NPs to facilitate cells often compromises the efficacy of the anticancer therapy with MTX (Zhao and Goldman 2003) . In addition, conventional MTX delivery strategies often lead to undesirable shortcomings, such as severe side effects associated with the treatment, including neurologic toxicity, renal failure and mucositis (Banerjee et al. 2002; Rubino 2001) . Chitosan (CS) is a naturally occurring polymer that has been attracting increasing attention in pharmaceutical and biomedical applications because of its biocompatibility, biodegradability, non-toxicity, cationic properties and bioadhesive characteristics (Bao et al. 2008; Fan et al. 2012) . Therefore, CS nanoparticles (NPs) are of great interest as drug delivery systems, including applications for cancer therapy (Chen et al. 2014; Deng et al. 2014; Trapani et al. 2011) . The ionotropic gelation technique is particularly suitable for the incorporation of pharmaceuticals, as it can be achieved in aqueous conditions (Agnihotri et al. 2004; Berger et al. 2004; Fan et al. 2012) . Moreover, the formation process is solely based on the electrostatic interaction of oppositely charged compounds and, thus, any chemical modification is not necessary. CS-based NPs containing MTX have been already reported in the literature, but most of them with the drawback of using a cross-linked agent (Chen et al. 2014; Jia et al. 2014; Luo et al. 2014; Wu et al. 2009 ). Likewise, there is considerable progress already achieved regarding the mechanisms underlying drug release from the nanostructures, with most of the current release methods being based on reactions that commonly occur in response to environmental factors, i.e., the acidic conditions of subcellular compartments (Li et al. 2012) . Therefore, the knowledge of this mechanism is the basis of the research of pH-responsive nanocarriers.
In this sense, and in an attempt to develop an efficient drug delivery device for cancer therapy, we reported a simple strategy for the preparation of pH-responsive MTXloaded CS-based NPs by using the ionic gelation method. Without cross-linkers and/or organic solvents, a bioactive amino acid-based surfactant with pH-sensitive properties was incorporated in the complexation process during NP preparation. This compound was added as a modifier into the formulation to achieve a greater antitumor activity of the encapsulated drug. The anionic amphiphile derived from N α ,N ε -dioctanoyl lysine with a sodium counterion (77KS) has pH-sensitive membrane-lytic behavior and low cytotoxicity (Nogueira et al. 2011a) , suggesting that it may be a specific adjuvant with the ability to destabilize the endosomal membrane in the mildly acidic environment and, thus, release more specifically and efficiently the drug inside the malignant cells (Lee et al. 2008) . Our group has previously published a study on the design of NPs based on medium molecular weight (MMW) CS and incorporating a lysine-based surfactant with a different counterion (77KL, with lithium counterion) (Nogueira et al. 2013 ). This study showed promising results, which therefore provided us the basis to continue the research in this field, seeking important progress in delivery strategies.
Finally, besides the preparation and characterization of CS-based NPs incorporating the surfactant 77KS, we evaluated the role of pH in the membrane-lytic activity of NPs and also in the in vitro drug release profile. In addition, to gain insight into the potential antitumor activity of NPs, the antiproliferative activity of both free and encapsulated drug was assessed using in vitro tumor cell models.
Experimental Chemicals and reagents
Chitosan (CS) of low molecular weight (LMW) (deacetylation degree, 75-85 %; viscosity, 20-300 cP according to the manufacturer's data sheet), pentasodium tripolyphosphate (TPP), 2,5-diphenyl-3,-(4,5-dimethyl-2-thiazolyl) tetrazolium bromide (MTT), neutral red (NR) dye, dimethyl sulfoxide (DMSO), phosphate-buffered saline (PBS) and trypsin-EDTA solution (0.5 g porcine trypsin and 0.2 g EDTA · 4Na per liter of Hanks′ Balanced Salt Solution) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Methotrexate (MTX, state purity 100.1 %) was purchased from SM Empreendimentos Farmacêuticos Ltda. (São Paulo, SP, Brazil). Acetonitrile was purchased from Tedia (Fairfield, USA). Fetal bovine serum (FBS) and Dulbecco's modified Eagle's medium (DMEM), supplemented with l-glutamine (584 mg/l) and antibiotic/antimicotic (50 mg/ ml gentamicin sulfate and 2 mg/l amphotericin B), were purchased from Vitrocell (Campinas, SP, Brazil). All other reagents were of analytical grade.
Surfactant included in the nanoparticles
An anionic amino acid-based surfactant derived from N α ,N ε -dioctanoyl lysine and with an inorganic sodium counterion (77KS) was included in the NP formulation. It has a molecular weight of 421.5 g/mol, a critical micellar concentration (CMC) of 3 × 10 3 µg/ml and its chemical structure is formed by two alkyl chains, each one with eight carbon atoms (Sánchez et al. 2006 (Sánchez et al. , 2007 . This surfactant was synthesized as previously described (Vives et al. 1999 ).
Nanoparticle preparation
CS-NPs were spontaneously obtained by ionotropic gelation technique, according to the methodology previously developed by Calvo et al. (1997) but with some modifications. The NPs were prepared with a selective CS:TPP:77KS ratio of 5:1:0.5 (w/w/w). Likewise, NPs omitting the surfactant and, thus, with CS:TPP ratio of 5:1 (w/w), were also prepared to perform comparative studies. Unloaded CS-NPs (unloaded-CS-NPs) were prepared by dropwise addition of a premixed solution containing the cross-linker TPP and the surfactant 77KS (both at 0.1 %, w/v) over the CS solution under magnetic stirring. Agitation was maintained for 20 min, under room temperature and dark conditions, to allow the complete formation of NPs. The CS solution was prepared at a concentration of 0.1 % (w/v) and was dissolved in acetic acid solution (1 %, v/v). The pH of the CS final solution was adjusted to 5.5 with 1 M NaOH (Gan et al. 2005) . Similarly, MTX-loaded CS-NPs (MTX-CS-NPs) were prepared following the same procedure, but adding MTX to a premixed TPP and 77KS solution, providing a final concentration of 0.07 % (w/v) of the antitumor drug (final ratio TPP:77KS:MTX 1:0.5:1, w/w/w).
Nanoparticle characterization
The mean hydrodynamic diameter and the polydispersity index (PDI) of the NPs were determined by dynamic light scattering (DLS) using a Malvern Zetasizer ZS (Malvern Instruments, Malvern, UK), without any dilution of the samples. Each measurement was performed using at least three sets of ten runs. The zeta potential (ZP) values of the NPs were assessed by determining electrophoretic mobility with the Malvern Zetasizer ZS equipment. The measurements were performed after dilution of the formulations in 10 mM NaCl aqueous solution (1:10 volume per volume), using at least three sets of ten runs. The pH measurements were determined directly in the NP suspensions, using a calibrated potentiometer (UB-10; Denver Instrument, Bohemia, NY, USA), at room temperature. Finally, the spectral properties of the model drug were assessed before its encapsulation and also after extraction from the NP structure. This assay was performed to verify the stability of MTX after entrapment into the NP matrix. The experiments were performed on a double-beam UV-VIS spectrophotometer (Shimadzu, Japan) model UV-1800, with a fixed slit width (2 nm), and a 10 mm quartz cell was used to obtain spectrum and absorbance measurements. The diluent optimized was 0.1 M sodium hydroxide.
Drug entrapment efficiency
The drug association efficiency was determined by the ultrafiltration/centrifugation technique using Amicon Ultra-0.5 Centrifugal Filters (10,000 Da MWCO, Millipore). The entrapment efficiency (EE %) was calculated by the difference between the total concentration of MTX found in the NP suspension after its complete dissolution in methanol and the free MTX concentration determined in the ultrafiltrate after separation of the NPs. The EE % of MTX in the NPs was measured using a previously validated reversed-phase high-performance liquid chromatography (RP-HPLC) method (Nogueira et al. 2014a ). The chromatographic analyses were carried out on a Shimadzu LC system (Shimadzu, Kyoto, Japan), using a Waters XBridgeTM C18 column (250 mm × 4.6 mm I.D., 5 μm). The mobile phase consisted of potassium phosphate buffer (0.05 M, pH 3.2):acetonitrile (86:14, v/v) and UV detection was set at 303 nm. The analytical method showed acceptable results for the specificity test (no interference of the NP components on the quantitative analysis) and also provided good linearity in the 1-30 µg/ml concentration range (r = 0.9999), precision (with a relative standard deviation lower than 1.5 %) and accuracy (mean recovery of 99.39 %).
In vitro release study
In vitro release assessments from MTX-loaded CS-NPs were carried out for 480 min in PBS at pH 7.4, 6.6 and 5.4. An aliquot of NPs (1 ml) was placed in a dialysis bag (Sigma-Aldrich, 14,000 MWCO) and suspended in 50 ml of PBS at 37 °C under gentle magnetic stirring (100 rpm). The withdrawal of 2 ml of the external medium from the system was done at predetermined time intervals and was filtered through a 0.45 µm membrane. An equal volume of fresh medium was replaced to maintain the sink conditions. The release of the free drug was also investigated in the same way. The cumulative release percentage of MTX at each time point was estimated by the RP-HPLC method described previously (Nogueira et al. 2014a ), using analytical curves obtained with the release medium (PBS at pH 7.4, 6.6 and 5.4) as diluents.
pH-dependent membrane-lytic activity of nanoparticles
The pH-dependent membrane-lytic activity of NPs was assessed using the hemolysis assay, with the erythrocytes as a model of the endosomal membrane (Akagi et al. 2010; Wang et al. 2007 ). Erythrocytes were isolated from human blood, which was obtained from discarding samples of the Clinical Analysis Laboratory of the University Hospital of Santa Maria. Tubes containing EDTA as anticoagulant were used for blood collection. Erythrocytes (25 μl of the suspension prepared in PBS) were incubated with increasing concentrations of unloaded-CS-NPs and MTX-CS-NPs suspended in PBS buffer of pH 7.4, 6.6 or 5.4. The extent and kinetics of hemolysis were assessed as reported earlier (Nogueira et al. 2011a) . The absorbance of the hemoglobin released in supernatants was measured at 540 nm by a Shimadzu UV-1800 spectrophotometer (Shimadzu, Kyoto, Japan).
Cytotoxicity assays-antitumor activity of free and encapsulated drug
The tumor cell lines HeLa (human epithelial cervical cancer) and MCF-7 (human breast cancer) were used as in vitro models to study the antitumor activity of MTX in its free and nanoencapsulated forms. Both cells were grown in DMEM medium (4.5 g/l glucose), supplemented by 10 % (v/v) FBS, at 37 °C with 5 % CO 2 . These cells were routinely cultured in 75 cm 2 culture flasks and harvested using trypsin-EDTA when the cells reached approximately 80 % confluence. HeLa (7.5 × 10 4 cells/ml) and MCF-7 (1 × 10 5 cells/ ml) cells were seeded into the 60 central wells of 96-well cell culture plates in 100 µl of complete culture medium. Cells were incubated for 24 h under 5 % CO 2 at 37 °C and the medium was then replaced with 100 µl of fresh medium supplemented by 5 % (v/v) FBS containing the treatments. Unloaded-CS-NPs were assayed in the 25-300 μg/ml concentration range, with these concentrations being based on the total composition of the formulation. In contrast, MTX-CS-NPs and free MTX were assessed in the 1-50 μg/ml concentration range and, in this case, the concentrations were based on the total amount of MTX in each sample. Untreated control cells were exposed to medium with 5 % (v/v) FBS only. The cell lines were exposed for 24 h to each treatment and their viability was assessed by two different assays, MTT and NRU (NR uptake).
The MTT end point is a measurement of cell metabolic activity and the assay is based on the first protocol described by Mosmann (1983) . On the other hand, the NRU assay is based on the protocol described by Borenfreund and Puerner (1985) and reflects the functionality of the lysosomes and cell membranes. After completion of the treatment time (24 h), the medium was removed and 100 µl of MTT in PBS (5 mg/ml) diluted 1:10 in medium without FBS was then added to the cells. Similarly, 100 µl of 50 µg/ml NR solution in DMEM without FBS was added to each well for the NRU assay. The microplates were further incubated for 3 h under 5 % CO 2 at 37 °C, after which the medium was removed and the wells of the NRU assay were washed once with PBS. Thereafter, 100 µl of DMSO was added to each well to dissolve the purple formazan product (MTT assay) or, similarly, 100 µl of a solution containing 50 % ethanol absolute and 1 % acetic acid in distilled water was added to extract the NR dye (NRU assay). After 10 min shaking at room temperature, the absorbance of the resulting solution was measured at 550 nm using a SpectraMax M2 (Molecular Devices, Sunnyvale, CA, USA) microplate reader. Cell viability for MTT and NRU was calculated as the percentage of tetrazolium salt reduced by viable cells in each sample or as the percentage of uptake of NR dye by lysosomes, respectively. The viability values were normalized by the untreated cell control (cells with medium only).
Hemocompatibility studies
Erythrocytes were isolated from human blood, as described for the experiments of pH-dependent membrane-lytic activity. Twenty-five microliter aliquots of erythrocyte suspension were exposed to unloaded-CS-NPs at concentrations of 100, 250 and 500 μg/ml (concentrations based on the total composition of the formulation), and to MTX-CSNPs or free MTX at concentrations of 10, 25 and 50 μg/ml (concentrations based on the total amount of MTX). The samples were incubated at room temperature for 10 min or 1 h and then centrifuged at 10,000 rpm for 5 min to stop the reaction. Absorbance of the hemoglobin released in supernatants was measured at 540 nm by a double-beam UV-VIS spectrophotometer (Shimadzu, Kyoto, Japan), model UV-1800.
Statistical analysis
Results are expressed as mean ± standard error of the mean (SE) and statistical analyses were performed using oneway analysis of variance (ANOVA) to determine the differences between the datasets, followed by Tukey's post hoc test for multiple comparisons, using SPSS ® software (SPSS Inc., Chicago, IL, USA). All in vitro experiments were performed at least three times, using three replicate samples for each formulation concentration tested. p < 0.05 was considered to be significant.
Results and discussion
The ionotropic gelation between CS, such as the polycation, and TPP, such as the polyanionic partner, leads to the formation of stable colloidal systems (Trapani et al. 2011) . Therefore, using the optimized operating parameters, this simple and solvent-free procedure was chosen to prepare the NPs in this work. The 5:1 chitosan to TPP ratio was confirmed as a stable and suitable ratio to carry out the following studies, as also done by Calvo et al. (1997) . Decreasing the chitosan to TPP ratio provokes an increasing turbidity, indicating a shift in the size variation of the particles to the larger end of the scale. Likewise, an excess of TPP may culminate in NP aggregation, once all the surface charges of CS have been annulled by excess polyanion (Fan et al. 2012) .
Before NP preparation, the pH of the CS solution was set at 5.5, as at this pH the NPs were smaller and have higher ZP (Gan et al. 2005) , suggesting their greater stability. Additionally, about 90 % of the amino groups of CS (pKa = 6.5) are protonated at pH 5.5 (Mao et al. 2010) , which ensures that the cross-linking process takes place to form CS-NPs. Likewise, a pH value of 5.5 would ionize most of the carboxylic groups of MTX, which allows attractive electrostatic interactions between the negatively charged drug molecules and positively charged CS molecules. The MTX molecule is a polyelectrolyte carrying two carboxyl groups (α-carboxyl and γ-carboxyl with pKa of 3.4 and 4.7, respectively) and a number of potentially protonated nitrogen functions, being the most basic with pKa of 5.7 (Rubino 2001) . Finally, it is worth mentioning that due to its low water solubility, MTX was dissolved in the basic solution of TPP (pH ~ 9.0) before cross-linking CS.
The choice of 77KS as a bioactive excipient in the NP formulation was based on our previous studies, which showed its pH-sensitive membrane-disruptive activity, together with improved kinetics in the endosomal pH range and low cytotoxic potential (Nogueira et al. 2011a, b) . 77KS was incorporated into the NPs at a concentration below its CMC, thereby indicating that this surfactant is presented in the formulation in its monomer form. Moreover, our group has already demonstrated that the inclusion of another surfactant from the same family (77KL) in the composition of polymeric NPs improved their in vitro antitumoral activity and also gave them a pH-responsive behavior (Nogueira et al. 2013) . It is noteworthy that this previous study gave us the basis to continue the research in the field of nanocarriers with pH-dependent properties.
Characterization of nanoparticles
Firstly, the stability of the drug after its encapsulation was assessed through spectral analysis, as shown in Fig. 1 . The UV-Vis spectrum of the drug extracted from NPs was similar to that obtained for the MTX solution before encapsulation, which proved the integrity of the MTX molecule after its entrapment into the NP matrix. In addition, the NPs were characterized for the mean particle size, PDI and ZP. Table 1 shows the characterization parameters of the NPs obtained in the presence and in the absence of MTX and/or 77KS. The hydrodynamic size of all NPs was in the range of 162-183 nm, with no considerable variations due to the presence of the drug. The presence of 77KS is accompanied by an increase in the size of NPs, but without significant differences. It is worth pointing out that these NPs with LMW-CS and 77KS have a diameter almost twofold lower than that of the NPs prepared with MMW-CS and 77KL (Nogueira et al. 2013 ). The small size of nanocarriers may constitute a great feature to improve the drug delivery to the tumor tissues and, more specifically, to the intracellular compartments of tumor cells (Elbakry et al. 2012; Huang et al. 2012) . Concerning the NP surface charge, positive ZP values (>22 mV) were detected for all formulations. ZP is a measurement of the electric charge at the surface of the particles and indicates the physical stability of colloidal systems. It should be noted that there was a slight decrease in the surface charge due to the presence Entrapment efficiency (EE %) -38.4 % -68.02 % of the drug. This reduced ZP value can be attributed to the electrostatic complexation of MTX with the free amino groups of CS, which, therefore, diminishes the net positive charge in the NP surface. Likewise, the entrapment efficiency of MTX showed a clear dependence on the presence of the surfactant in the formulation. In the absence of 77KS, the EE % obtained (~68 %) was significantly higher than the value obtained in the presence of 77KS (~38 %). The high incorporation capacity of CS-NPS without 77KS (CS:TPP 5:1, w/w) is probably related to the chemical nature of the drug and to its interaction with the NP structure at the pH value of the experimental conditions. On the other hand, the lower encapsulation efficiency of the CS-NPs containing the surfactant (CS:TPP:77KS 5:1:0.5, w/w/w) might be attributed to the competition between MTX and 77KS, both negatively charged, for the electrostatic complexation with the positively charged CS molecules.
In vitro release study
The release profiles of MTX from the CS-NPs showed a first phase with an initial burst release of 57 % in the first 60 min at pH 7.4, as shown in Fig. 2 . This is possibly due to the drug molecules dispersing close to the NP surface. Considering the electrostatic attraction existing between the negatively charged drug and the positively charged polymer, we can assume that the MTX molecules are both adsorbed at the particle surface (Gan and Wang 2007) and entrapped/embedded into CS nano-matrix by hydrogen bonding and hydrophobic forces (Calvo et al. 1997) . Therefore, the way by which the drug is associated with the carrier (adsorption or encapsulation) might determine its release rate from the matrix. In the second phase, a constant release of the drug was observed up to 480 min, which can be a result of the diffusion of MTX through the polymer wall. A control experiment using free MTX was also carried out under similar conditions, and complete diffusion across the dialysis membrane was found to occur within 240 min.
When the studies were performed in acidic environment, the release rate was accelerated, which confirms the pH-dependent release pattern of this nanostructure. The triggered release of payload under acidic conditions is probably attributed to the pH-responsive activity of 77KS (Nogueira et al. 2011a ). The cumulative MTX release at pH 6.6 and 5.4 was in general significantly faster (p < 0.05) than at pH 7.4. At 480 min, 96 and 100 % of MTX was released at pH 6.6 and 5.4, respectively, while only 89 % of drug release was reached at pH 7.4. The total drug release at acidic conditions might be attributed to swelling and degradation of the compact NPs (Gan and Wang 2007) . Additionally, it is noteworthy that the accelerated release at acidic conditions might promote an improved drug delivery in the acidic extracellular pH of tumors (pH e ~6.6) (Na et al. 2003) . Nevertheless, the pH-dependent pattern observed here was not as effective as in our previous work (Nogueira et al. 2013) , in which MMW-CS and the surfactant 77KL as bioactive adjuvant in the NP formulation were used. The faster release achieved here could be attributed to the formulation of NPs with LMW-CS, as it was previously described that the total drug release decreased significantly with increasing CS molecular weight (Gan and Wang 2007) . Furthermore, these overall results could be attributed to the lower encapsulation efficiency obtained herein with the surfactant 77KS.
pH-dependent membrane-lytic activity of nanoparticles The hemolysis assay, with the erythrocyte as a model for the endosomal membrane, was applied herein to assess whether the presence of 77KS provides to the NPs a pHresponsive membrane-lytic behavior. Firstly, it is worth mentioning that strong correlations have been reported between hemolytic activity and endosomal disturbance induced by membrane-disruptive agents (Chen et al. 2009; Lee et al. 2010; Plank et al. 1994 ). This biological correlation justifies, thus, the use of erythrocytes as a model for endosomal membrane.
The membrane-lytic activity of the NPs as a function of concentration, with varying pH and incubation time, is shown in Fig. 3 . Primarily, we evaluated the membrane lysis induced by unloaded and MTX-loaded CS-NPs incorporating 77KS (Fig. 3a, b, respectively) . At physiological pH, negligible hemolysis was observed after 10 min incubation, while 8.5 and 25 % of hemolysis was observed after 60 min incubation with NPs loading or not of the drug, respectively. As the pH decreased to 6.6 or 5.4, the membrane-lytic activity of unloaded and MTX-loaded CSNPs increased significantly (p < 0.05) in a dose-dependent manner. After 60 min incubation, unloaded-CS-NPs were 2.81-and 3.17-fold more hemolytic at pH 6.6 and 5.4 than at pH 7.4, respectively. Likewise, and even more efficiently, MTX-CS-NPs were 4.06-and 9.35-fold more membranelytic active in environments simulating early and late endosomal compartments, respectively. These results demonstrated that entrapment of MTX into NPs did not change their pH-responsive behavior. Finally, to confirm that the pH-sensitive membrane-lytic activity of NPs was really attributed to the surfactant, unloaded and MTX-loaded CS-NPs were prepared without 77KS and submitted to the same assay procedure. Negligible or low hemolysis rates were obtained in all tested conditions, proving the lack of pH-responsive behavior of these NPs in the absence of 77KS (Fig. 3c, d , respectively). The hemolysis of nonencapsulated MTX was also assessed, but insignificant membrane lysis was obtained in the entire pH range (data not shown). Therapeutic agents, including antitumor drugs, act at intracellular sites and, thus, their clinical efficacy depends on efficient intracellular trafficking (Hu et al. 2007; Plank et al. 1998 ). As cells usually take up drug nanocarriers via endocytosis, an important challenge for the intracellular delivery of therapeutic compounds is to circumvent the non-productive trafficking from endosomes to lysosomes, where degradation may occur (Stayton et al. 2000) . Therefore, the design of pH-responsive nanostructures is considered a great approach to facilitate the drug release into the cytosol by destabilizing endosomal membranes under mildly acidic conditions (Chen et al. 2009 ). Agents commonly used to promote NP escape/release from endosomes include pH-sensitive peptides and surfactants, pH-buffering polymers, and fusogenic lipids (Li et al. 2012; Nogueira et al. 2014b) .
In this sense, we prepared polymeric NPs incorporating a surfactant that showed high efficiency at disrupting cell membranes within the pH range characteristic of the endosomal compartments (Nogueira et al. 2011a) . As expected, the NPs containing 77KS presented a clear membrane-lytic behavior dependent on pH, suggesting their potential ability to promote triggered release of entrapped drug in a pH-responsive fashion. The enhanced hemolysis induced by NPs at acidic conditions could be explained firstly by the electrostatic attraction of the NPs to the negatively charged cell membranes and, secondly, by a modification in the hydrophobic/hydrophilic balance of 77KS at the pH range of endosomes. The carboxylic group of 77KS seems to become protonated at acidic conditions, which makes it non-ionic and enhances its hydrophobicity. These hydrophobic segments can insert into lipophilic regions of lipid bilayers, causing membrane solubilization or altering the permeability of the membrane, hence, inducing cell lysis.
In vitro assessments of antitumor activity
The in vitro antitumor activity of MTX-CS-NPs and free MTX was assessed using two different tumor cell lines, HeLa and MCF-7. We chose the in vitro model systems to perform this study, as they provide a rapid and effective means to assess NPs for a number of toxicological end points and mechanism-driven responses. Primarily, we evaluated if the unloaded-CS-NPs have any cytotoxic effect, which can be attributed especially to the presence of the surfactant (Nogueira et al. 2011b) . Figure 4a demonstrates that unloaded-CS-NPs have low or negligible cytotoxicity against both cell lines and display at least 80 % of cell viability.
As a second step, we studied the antiproliferative activity of the NPs containing the drug, and our results clearly proved that the cytotoxicity of MTX-CS-NPs incorporating 77KS was greater than that of free drug against both tumor cells (Fig. 4b-e) . By increasing the drug concentration, the antitumor activity of NPs became higher in comparison to the same concentration range of free MTX. Low to moderate cytotoxic effects were achieved for free MTX, whereas MTX encapsulated into NPs significantly reduced cell growth. For example, it can be evaluated from Fig. 4d that, by the MTT assay, the MCF-7 cell viability at the 50 µg/ml drug concentration was decreased from 71.14 % for free MTX to 40.80 % for MTX-CS-NPs (30.34 % decrease in cell viability, p < 0.05). Likewise, but with low intensity, the viability of HeLa cells was decreased from 79.87 % for free MTX to 61.57 % for MTX-CS-NPs (18.30 % decrease in cell viability, p < 0.05) (Fig. 4b) . On the other hand, the NRU assay displayed lower sensitivity to detect the cytotoxic effects of free and encapsulated drug in both cell lines. No significant differences were observed in HeLa cells (Fig. 4c ), but this assay also detected greater activity of NPs in MCF-7 cells at the highest concentrations assayed (Fig. 4e) . It is noteworthy that MTT was the most sensitive viability assay for detecting the cytotoxic effects of the NPs, regardless of the cell line. The MTT assay determines cell metabolic activity within the mitochondrial compartment, while NRU end point measures membrane integrity. This implies that NPs primarily exerted toxicity on the mitochondrial compartment after cellular internalization, while the cell membranes were affected only at a later stage. This finding could be related to the mechanism of action of the drug. MTX is a potent inhibitor of the enzyme DHFR, which plays a key role in the synthesis of purines and thymine and, thus, leads to a blockage of DNA and RNA synthesis and eventually to cell death (Rubino 2001) . Therefore, MTX is a chemotherapeutic agent that mainly inhibits cell proliferation by acting in the intracellular sites, which justifies its lower effects on cell membrane integrity.
Due to its high polarity (at the neutral pH of biological fluids, it is present mainly in the doubly anionic species), MTX can cross the cell membrane only with difficulty and, therefore, is transported into the cells by a specific, highaffinity carrier system, or by a passive diffusion mechanism, which can be limited by the high ionization state of MTX at physiological pH (Rubino 2001) . This mechanism could justify the general low activity of free MTX in comparison with its encapsulated form. Likewise, MTX does not exert its cytotoxic activity only toward neoplastic cells, but also targets other tissues, thus determining a range of side effects. Therefore, to overcome the undesirable toxicity of MTX and to circumvent the risks associated with the administration of the free drug, considerable research efforts have been directed toward novel nanotechnologybased MTX delivery approaches (Chen et al. 2007; Kuznetsova et al. 2012; Thomas et al. 2012) . Here, the enhanced cytotoxicity of MTX via the pH-responsive NPs means that a significant reverse effect of drug resistance could has occurred. Moreover, nanoparticulate systems may reduce the resistance effects that characterize many anticancer drugs by a mechanism of cell internalization of the drug by endocytosis, by lowering drug efflux from the cells and, in the case of pH-responsive NPs, by allowing an effective drug release from the endosomes to cell cytosol (Dong and Mumper 2010) . Therefore, the pH-dependent membranelytic activity of the MTX-CS-NPs (see the previous section) seems to be directly related to their enhanced therapeutic efficacy compared to the native drug.
Finally, we can highlight that during this study, we observed differences in the sensitivity of cell lines and viability assays to each treatment. In view of that, we support the idea that complementary assays based on various cell mechanisms, as well as a combination of cell culture models, are needed to raise the information output and the reliability of the results.
Hemocompatibility studies
The assessment of the hemocompatibility of a nanocarrier is indispensable for frequent intravenous dosing (Kuznetsova and Vodovozova 2014). Therefore, as the proposed nanocarriers were intended for intravenous administration, we evaluated if they caused any toxicological reaction to the erythrocytes. The hemocompatibility of unloaded and MTX-loaded CS-NPs, both containing the surfactant 77KS, was studied by hemolysis experiments (Fig. 5) . The release of hemoglobin was used to quantify their erythrocytedamaging properties. The unloaded-CS-NPs were nonhemolytic (less than 5 %) at the lower concentrations, and showed slight hemolysis at the highest concentration and after 1 h incubation. In contrast, the NPs containing MTX were almost non-hemolytic regardless of the concentration and the incubation time (maximum 8 % hemolysis). Likewise, free MTX was non-hemolytic in all the conditions (data not shown). Fortunately, these results were in contrast with those previously reported for other nanoformulations containing MTX (Kuznetsova and Vodovozova 2014; Nogueira et al. 2013) , in which the encapsulated drug displayed higher hemoreactivity than its free solution. Altogether, the obtained results suggest the hemocompatibility of the designed pH-sensitive NPs. MTT and NRU assays, respectively. Data are expressed as the mean of three independent experiments ± SE. Statistical analyses were performed using ANOVA followed by Tukey's multiple comparison test. a Significantly different from HeLa cells (p < 0.05). *p < 0.05 and **p < 0.01 denote significant differences from free MTX
Conclusions
In summary, we have demonstrated a simple and solventfree approach to prepare pH-responsive CS-NPs by incorporating a biocompatible amino acid-based surfactant in the ionotropic complexation process. The obtained NPs presented a suitable nanosize and displayed accelerated release of MTX by decreasing the pH from 7.4 to 5.4. The inclusion of 77KS on the formulation clearly gives it a pH-sensitive membrane-lytic behavior, which suggests that these NPs act as a potential intracellular delivery system. Outstandingly, pH-responsive CS-NPs significantly improved the in vitro antitumor activity of MTX with respect to the free drug in MCF-7 cell culture and, to a lesser extent, in HeLa cells. Based on the overall results, the conclusion that may be reached from this study is that this nanocarrier system represents a promising strategy for the administration of antitumor drugs in cancer therapy, which merits further investigations under in vivo conditions to confirm this premise. 
